<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164214</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002954-29</org_study_id>
    <secondary_id>2011-14</secondary_id>
    <nct_id>NCT02164214</nct_id>
  </id_info>
  <brief_title>Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?</brief_title>
  <official_title>DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TWEAK (TNF weakly inducer of apoptosis) is a type II-transmembrane protein, member of the TNF
      ligand superfamily that can be cleaved to function as a soluble cytokine. Depending on target
      cell type, TWEAK triggers multiple cellular responses ranging from modulation of inflammation
      to cell death when it binds to its main receptor, Fn 14. Our team has been the first to
      describe pro-inflammatory effects of TWEAK during central nervous system inflammation.
      Various data support the possibility that TWEAK produced by synovial macrophages may
      contribute to chronic synovitis in animal models and in humans. In psoriatic arthritis
      (PsoA), anti-TNF therapy has been successful concording with the key role of TNF in the
      pathogenesis of this disease and the generation by psoriatic patients of neutralizing
      anti-TNF autoantibodies referred as &quot;beneficial autoimmunity to pro-inflammatory mediators&quot;.
      In 2010, Van Kuijk et al. have described a high expression of TWEAK in the inflammatory
      synovial of PsoA and rheumatoid arthritis (RA) patients before and after anti-TNF therapy.
      The role of TNF-alpha in the regulation of TWEAK expression remains unclear.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum levels of soluble TWEAK</measure>
    <time_frame>42 months</time_frame>
    <description>samples blood before and after etanercept Treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inflammatory Rheumatism</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>patients PSORIATIC ARTHRITIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etanercept Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients RHEUMATOID ARTHRITIS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept Treatment</intervention_name>
    <arm_group_label>patients PSORIATIC ARTHRITIS</arm_group_label>
    <arm_group_label>patients RHEUMATOID ARTHRITIS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  · Group RhPso :

          -  Fill(Perform) the criteria CASPAR of the Rheumatism psoriasic (Taylor W, on 2006)

          -  rheumatoid Absence of factor and antibody anti-CCP(anti-post office account) (cyclic
             citrulline peptide) in the serum

          -  Indication established to begin a treatment with etanercept

             · Group PR

          -  Fill(Perform) the criteria of the ACR (American College of Rheumatology) for PR
             (revised in 1987) (Arneth FC, on 1988)

          -  Presence of antibody anti-CCP(anti-post office account) in the serum

          -  Indication established to begin a treatment with etanercept

        Exclusion Criteria:

          -  Minors(Miners)

          -  pregnant or breast-feeding Women

          -  Adults under guardianship

          -  Nobody staying in a sanitary or social establishment

          -  Persons in emergency situation and/or not beneficiaries of a national insurance scheme

          -  Private persons of freedom

          -  Arthritis or not labelled polyarthritis

          -  Contraindication established in the treatment(processing) by etanercept

          -  PUVAthérapie or cyclosporine or high dose of corticosteroid therapy (except
             intra-articular infiltration) or other anti-TNF treatment(processing) in two months
             preceding the inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Rheumatic Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

